This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Re, D. Articles by Diehl, V. Search for Related Content PubMed PubMed Citation Articles by Re, D. Articles by Diehl, V.

Molecular Pathogenesis of Hodgkin's Lymphoma

Daniel Re, Ralf Küppers, Volker Diehl

From the Department I of Internal Medicine, University of Cologne, Cologne; Institute for Cell Biology (Tumor Research), University of Duisburg-Essen Medical School, Essen, Germany; and the Burnham Institute, La Jolla, CA

Address reprint requests to Daniel Re, MD, The Burnham Institute, John Reed Laboratory, 10901 N. Torrey Pines Rd., La Jolla, CA 92037; e-mail: dre{at}burnham.org.

According to the WHO classification, Hodgkin's lymphoma (HL) is subdivided into a classical variant and a nodular lymphocyte predominant variant which are characterized by the presence of Hodgkin's and Reed-Sternberg (H-RS) cells or lymphocytic and histiocytic (L&H) cells, respectively. This article reviews genetic characteristics and transcriptional changes of H-RS and L&H cells, including recent knowledge about transforming mechanisms and signaling pathways that contribute to the antiapoptotic phenotype displayed by H-RS and L&H cells. We also discuss major cellular and molecular mediators contributing to the establishment and maintenance of a reactive background in HL-affected tissues. We believe that an in-depth understanding of the pathogenesis of HL will eventually lead to the development of novel biologically based therapeutic strategies in the near future.

Supported by the Friedrich and Maria Sophie Moritsche Stiftung, the Deutsche Krebshilfe, and the Deutsche Forschungsgemeinschaft.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				A. Carbone, A. Gloghini, and G. Dotti EBV-Associated Lymphoproliferative Disorders: Classification and Treatment Oncologist, May 1, 2008; 13(5): 577 - 585. [Abstract] [Full Text] [PDF]

				B. Hirsch, M. Hummel, S. Bentink, F. Fouladi, R. Spang, R. Zollinger, H. Stein, and H. Durkop CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma Cells Am. J. Pathol., February 1, 2008; 172(2): 510 - 520. [Abstract] [Full Text] [PDF]

				P. Juszczynski, J. Ouyang, S. Monti, S. J. Rodig, K. Takeyama, J. Abramson, W. Chen, J. L. Kutok, G. A. Rabinovich, and M. A. Shipp The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma PNAS, August 7, 2007; 104(32): 13134 - 13139. [Abstract] [Full Text] [PDF]

				E. Drakos, A. Thomaides, L. J. Medeiros, J. Li, V. Leventaki, M. Konopleva, M. Andreeff, and G. Z. Rassidakis Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma Clin. Cancer Res., June 1, 2007; 13(11): 3380 - 3387. [Abstract] [Full Text] [PDF]

				J. S. Abramson T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. Oncologist, April 1, 2006; 11(4): 384 - 392. [Abstract] [Full Text] [PDF]

				J. F. Garcia Classical Hodgkin lymphoma: an epigenetically determined disease? Blood, March 15, 2006; 107(6): 2217 - 2218. [Full Text] [PDF]